Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Q5LF
|
||||
| Former ID |
DNC000321
|
||||
| Drug Name |
BIO-1211
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Asthma [ICD10:J45] | Phase 2 | [541708] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C36H48N6O9
|
||||
| InChI |
InChI=1S/C36H48N6O9/c1-20(2)17-26(38-29(43)18-23-12-14-24(15-13-23)37-36(51)40-25-10-7-6-9-22(25)5)32(46)39-27(19-30(44)45)33(47)41-31(21(3)4)34(48)42-16-8-11-28(42)35(49)50/h6-7,9-10,12-15,20-21,26-28,31H,8,11,16-19H2,1-5H3,(H,38,43)(H,39,46)(H,41,47)(H,44,45)(H,49,50)(H2,37,40,51)/t26-,27-,28-,31-/m0/s1
|
||||
| InChIKey |
NVVGCQABIHSJSQ-KFZSMJGVSA-N
|
||||
| CAS Number |
CAS 187735-94-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Integrin alpha-4 | Target Info | Antagonist | [535024] | |
| KEGG Pathway | PI3K-Akt signaling pathway | ||||
| Focal adhesion | |||||
| ECM-receptor interaction | |||||
| Cell adhesion molecules (CAMs) | |||||
| Hematopoietic cell lineage | |||||
| Leukocyte transendothelial migration | |||||
| Intestinal immune network for IgA production | |||||
| Regulation of actin cytoskeleton | |||||
| Leishmaniasis | |||||
| Hypertrophic cardiomyopathy (HCM) | |||||
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | |||||
| Dilated cardiomyopathy | |||||
| PANTHER Pathway | Integrin signalling pathway | ||||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | ||||
| Integrin family cell surface interactions | |||||
| Arf6 trafficking events | |||||
| CXCR4-mediated signaling events | |||||
| Plexin-D1 Signaling | |||||
| a4b7 Integrin signaling | |||||
| Beta5 beta6 beta7 and beta8 integrin cell surface interactions | |||||
| VEGFR3 signaling in lymphatic endothelium | |||||
| Alpha4 beta1 integrin signaling events | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.